Cheng Chi Fung 4
Research Summary
AI-generated summary
Credo (CRDO) CTO Cheng Chi Fung Sells 27,500 Shares
What Happened Cheng Chi Fung, Credo Technology Group's Chief Technology Officer and director, sold a total of 27,500 ordinary shares in open‑market transactions on March 11, 2026, generating approximately $3,233,981 in proceeds. The sales were reported in multiple tranches: 200 @ $114.02 ($22,804); 4,200 @ $115.23 ($483,985); 3,821 @ $115.88 ($442,774); 4,079 @ $117.16 ($477,892); 5,700 @ $117.97 ($672,434); 6,144 @ $119.13 ($731,916); 3,256 @ $119.81 ($390,115); and 100 @ $120.61 ($12,061). These were sales (not purchases); sales are often routine and do not necessarily signal a change in company outlook.
Key Details
- Transaction date: March 11, 2026; Form 4 filed March 13, 2026 (timely filing).
- Total sold: 27,500 shares for about $3,233,981 in aggregate.
- Execution: Open‑market sales executed in multiple trades; several lots reported as weighted averages with price ranges (see footnotes F2–F9 for per‑lot ranges).
- Plan/trust: Sales were effected pursuant to a Rule 10b5‑1 trading plan adopted by the Cheng Huang Family Trust on Sept 5, 2025 (F1). The shares sold were held by the Cheng Huang Family Trust; Cheng Chi Fung and his spouse are trustees and beneficiaries (F3); the reporting person disclaims beneficial ownership except to the extent of pecuniary interest.
- Shares owned after transaction: Not disclosed in the provided excerpt of the filing.
- Additional note: The filing states weighted‑average prices and that full breakdowns of individual trade prices/quantities are available upon request to the SEC staff, issuer, or security holders.
Context 10b5‑1 plans permit insiders or their trusts to trade according to a pre‑arranged schedule and are commonly used to avoid questions about timing; transactions under such plans are often routine (e.g., diversification, tax planning) rather than a direct signal about company prospects. For retail investors, insider purchases tend to be more informative about confidence in the business than routine trust sales; these reported sales should be considered factual disclosures, not a definitive indicator of management’s view.